FDMT Valuation

4D Molecular Therapeutics Inc

Add to Watchlist

Advanced Chart

7.270

+0.01(0.138%)1D

Overview
Forecast
Valuation
Earnings

FDMT Relative Valuation

FDMT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, FDMT is overvalued; if below, it's undervalued.

Historical Valuation

4D Molecular Therapeutics Inc (FDMT) is now in the Fair zone, suggesting that its current forward PS ratio of 55.54 is considered Fairly compared with the five-year average of -5.95. The fair price of 4D Molecular Therapeutics Inc (FDMT) is between 4.78 to 15.79 according to relative valuation methord.

Relative Value

Fair Zone

4.78-15.79

Current Price：7.27

Fair

-1.36

Trailing

Forward

0.94

EV/EBITDA

4D Molecular Therapeutics Inc. (FDMT) has a current EV/EBITDA of 0.94. The 5-year average EV/EBITDA is -3.49. The thresholds are as follows: Strongly Undervalued below -12.35, Undervalued between -12.35 and -7.92, Fairly Valued between 0.95 and -7.92, Overvalued between 0.95 and 5.38, and Strongly Overvalued above 5.38. The current Forward EV/EBITDA of 0.94 falls within the Historic Trend Line -Fairly Valued range.

0.92

EV/EBIT

4D Molecular Therapeutics Inc. (FDMT) has a current EV/EBIT of 0.92. The 5-year average EV/EBIT is -3.34. The thresholds are as follows: Strongly Undervalued below -11.97, Undervalued between -11.97 and -7.66, Fairly Valued between 0.97 and -7.66, Overvalued between 0.97 and 5.28, and Strongly Overvalued above 5.28. The current Forward EV/EBIT of 0.92 falls within the Historic Trend Line -Fairly Valued range.

55.54

4D Molecular Therapeutics Inc. (FDMT) has a current PS of 55.54. The 5-year average PS is 129.64. The thresholds are as follows: Strongly Undervalued below -155.82, Undervalued between -155.82 and -13.09, Fairly Valued between 272.38 and -13.09, Overvalued between 272.38 and 415.11, and Strongly Overvalued above 415.11. The current Forward PS of 55.54 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

4D Molecular Therapeutics Inc. (FDMT) has a current P/OCF of 0.00. The 5-year average P/OCF is -7.23. The thresholds are as follows: Strongly Undervalued below -17.32, Undervalued between -17.32 and -12.28, Fairly Valued between -2.18 and -12.28, Overvalued between -2.18 and 2.86, and Strongly Overvalued above 2.86. The current Forward P/OCF of 0.00 falls within the Overvalued range.

-0.91

P/FCF

4D Molecular Therapeutics Inc. (FDMT) has a current P/FCF of -0.91. The 5-year average P/FCF is -5.96. The thresholds are as follows: Strongly Undervalued below -14.96, Undervalued between -14.96 and -10.46, Fairly Valued between -1.46 and -10.46, Overvalued between -1.46 and 3.04, and Strongly Overvalued above 3.04. The current Forward P/FCF of -0.91 falls within the Overvalued range.

4D Molecular Therapeutics Inc (FDMT) has a current Price-to-Book (P/B) ratio of 0.47. Compared to its 3-year average P/B ratio of 1.81 , the current P/B ratio is approximately -73.96% higher. Relative to its 5-year average P/B ratio of 2.08, the current P/B ratio is about -77.28% higher. 4D Molecular Therapeutics Inc (FDMT) has a Forward Free Cash Flow (FCF) yield of approximately -77.89%. Compared to its 3-year average FCF yield of -25.66%, the current FCF yield is approximately 203.55% lower. Relative to its 5-year average FCF yield of -21.30% , the current FCF yield is about 265.75% lower.

0.47

P/B

Median3y

1.81

Median5y

2.08

-77.89

FCF Yield

Median3y

-25.66

Median5y

-21.30

Competitors Valuation Multiple

The average P/S ratio for FDMT's competitors is 14.64, providing a benchmark for relative valuation. 4D Molecular Therapeutics Inc Corp (FDMT) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -50.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

FDMT.O

4D Molecular Therapeutics Inc

CARGO Therapeutics Inc

Monopar Therapeutics Inc

Loss

211.38M

INBX.O

Inhibrx Biosciences Inc

Eupraxia Pharmaceuticals Inc

Loss

190.59M

Performance Decomposition

Market capitalization of FDMT decreased by 51.57% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -115.72K to -342.66K.

The secondary factor is the Revenue Growth, contributed -50.00%to the performance.

Overall, the performance of FDMT in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-50.00%

28.00K → 14.00K

Revenue Growth

196.11%

-115.72K → -342.66K

Margin Expansion

-197.68%

1.54 → -1.51

P/E Change

-51.57%